EN DE

Heren Health Co (300550) Fair Value & Analysis

Healthcare · CN · Market cap 3.9B CNY

HH Heren Health Co 300550 · SHE
Price¥11.94
Fair Value¥3.99
Upside-66.6%
Quality66/100
Watch Heren Health Co for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 9.8% net margin
Low debt · generates free cash flow
0.21% dividend yield
Mixed vs. peers (6/14)
Narrow moat 29/100
Evidence: High Range ¥3.00 – ¥4.99 Share as image

Fair value as of: Jul 9, 2026

From 24 valuation models · updated 32 days ago

Fair value updated Jul 9, 2026, revised from ¥6.05 to ¥3.99 (−34.0%) since Jun 24, 2026. Share price −18.8% over the past month.

A solid business, but screening 67% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (¥4.99). The favourable scenario is already priced in.
  • Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

¥18.80 ¥7.79 Fair Value ¥3.99 Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.

How to read this chart

60‑month range ¥7.79 – ¥18.80 · fair‑value band ¥3.00 – ¥4.99 · the ¥11.94 price screens above the ¥3.99 fair value. Dashed = 300-day average. As of Jul 9, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Heren Health Co (300550) currently trades at ¥11.94, while our model-based Fair Value estimate is ¥3.99, implying the stock looks roughly 66.6% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Heren Health Co generated revenue of 433M CNY at a net margin of 9.8%. Revenue declined 3.0% year over year. It earns a return on equity of 3.9%. The stock trades on a trailing P/E of 93.1. Fundamentals as of Jul 9, 2026

Our scenario range runs from ¥3.00 (bear case) to ¥4.99 (bull case); at ¥11.94, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -67%, 300550 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF ¥5.55 ¥7.76 ¥11.15 80
Residual Income ¥3.23 ¥3.19 ¥2.84 76
Rev-Margin DCF ¥4.99 ¥6.94 ¥9.33 74
All 24 models by family
DCF Models
FCF DCF ¥5.54 ¥7.87 ¥11.52 38
Owner Earnings ¥3.38 ¥4.34 ¥5.84 31
5Y Revenue Exit ¥4.99 ¥6.95 ¥9.51 39
5Y EBITDA Exit ¥5.81 ¥8.56 ¥11.88 41
5Y P/E Exit ¥4.91 ¥6.80 ¥8.84 38
10Y Revenue Exit ¥5.06 ¥6.92 ¥9.55 36
10Y EBITDA Exit ¥5.67 ¥8.04 ¥11.39 37
10Y P/E Exit ¥5.10 ¥6.81 ¥9.02 35
Earnings-Based
Graham-Dodd ¥1.23 ¥4.75 ¥6.44 54
Lynch FV ¥1.16 ¥1.66 ¥2.15 50
PEG = 1.0 ¥1.16 ¥1.66 ¥2.15 46
EPV ¥4.50 ¥4.91 ¥5.27 59
Multiples
P/E Multiple ¥3.00 ¥3.99 ¥4.99 63
P/S Multiple ¥2.31 ¥3.09 ¥3.86 58
P/B Multiple ¥2.31 ¥3.09 ¥3.86 55
EV/EBIT ¥5.97 ¥7.33 ¥8.70 53
EV/EBITDA ¥6.40 ¥7.90 ¥9.41 54
EV/Revenue ¥4.79 ¥6.05 ¥7.30 43
Asset-Based
NCAV (Graham) ¥2.19 ¥2.94 ¥4.39 50
Growth DCF
Growth DCF ¥5.55 ¥7.76 ¥11.15 80
Rev-Margin DCF ¥4.99 ¥6.94 ¥9.33 74
Economic Profit
Residual Income ¥3.23 ¥3.19 ¥2.84 76
ROIC Compounder ¥4.54 ¥5.31 ¥6.36 72
Growth Earnings
Growth-Adj P/E ¥2.16 ¥3.08 ¥4.01 68

Widest divergence: Growth DCF (¥6.94) versus Earnings-Based (¥1.66). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) 433M CNY
Revenue growth (YoY) -3.0%
Net margin 9.8%
Return on equity 3.9%
Free cash flow 83.9M CNY FY2025
P/E ratio 93.1
More key figures
Operating margin -6.1%
EPS (TTM) ¥0.1600
Dividend yield 0.2%
EPS growth (YoY) -8.3%

Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 66/100

Of which business quality 69 · Market factors (momentum, volatility) 38

Profitability 30
Margins and returns on capital today
Quality Growth 41
Are margins and returns improving?
Cashflow 83
Earnings quality: real cash, not paper profit
Fin. Strength 99
Balance sheet, leverage, solvency risk
Investment 77
Disciplined investing over empire-building
Low Volatility 58
Calm price path (market factor)
Momentum 35
Price trend over the last 3–12 months (market factor)
52W Momentum 21
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Heren Health Co.,Ltd. provides medical solutions to hospitals and governments in China. The company offers solutions to smart hospitals, healthy city, smart medical consortium, and medical treatment. Heren Health Co.,Ltd. was incorporated in 2010 and is headquartered in Hangzhou, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Heren Health Co reported revenue of ¥435M in FY2025 versus ¥464M in FY2021, a compound −1.6%/yr. Reported net income was ¥47.7M in FY2025, compounding +8.2%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
435M CNY
Latest YoY
+7.2%
Avg. growth/yr (3Y)
+6.5%
Avg. growth/yr (5Y)
−0.9%
Avg. growth/yr (14Y)
+24.9%
Revenue −1.6%/yr
FY21 ¥464M
FY22 ¥360M
FY23 ¥439M
FY24 ¥406M
FY25 ¥435M
Net income +8.2%/yr
FY21 ¥34.8M
FY22 −¥83.3M
FY23 ¥39.1M
FY24 ¥39.3M
FY25 ¥47.7M

300550 screens 67% overvalued. Compare with Veeva Systems Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Heren Health Co Fair Value". https://www.fairvalue-calculator.com/stock/300550

Peer Group

Health Information Services · 127 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 66 · Top 25%
Fair Value upside −67% · Below median
Return on equity (TTM) 4% · Above median
Return on assets 2% · Above median
Net margin (TTM) 10% · Top 25%
Operating margin (TTM) -6% · Below median
Revenue growth -3% · Below median
Dividend yield (TTM) 0.2% · Bottom 25%
Debt / equity 0.04× · Lower than median

Valuation Multiples vs Health Information Services median · lower = cheaper

P/E (TTM) 93.1× · Pricier than 75% of peers
P/B 3.39× · Pricier than median
P/S (TTM) 9.04× · Pricier than 75% of peers
P/FCF 6.9× · Cheaper than median
EV/EBITDA 71.8× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 0 · sector 33
PAST 16 · sector 7
HEALTH 98 · sector 98
DIVIDEND 4 · sector 35

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $190.12 $95.12 -50%
Pro Medicus Limited PME A$194.84 A$23.74 -88%
BrightSpring Health Services, Inc BTSG $68.16 $21.31 -69%
HealthEquity, Inc HQY $97.67 $56.63 -42%
Hinge Health, Inc HNGE $88.80 $24.03 -73%
10x Genomics, Inc TXG $45.75 $17.18 -62%
Waystar Holding WAY $22.69 $12.86 -43%
Doximity, Inc DOCS $22.21 $17.18 -23%
Privia Health Group PRVA $28.10 $5.30 -81%
Inventurus Knowledge Solutions Limited IKS ₹1,846 ₹860.28 -53%

Compare Heren Health Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Heren Health Co (300550) overvalued or undervalued?
As of Jul 9, 2026, our model estimates a fair value of ¥3.99 versus a price of ¥11.94, about −67% (overvalued).
What is the fair value of 300550?
Our model-based fair value for Heren Health Co is ¥3.99 (as of Jul 9, 2026), built from audited fundamentals. The current price is ¥11.94.
What is the quality score of 300550?
Heren Health Co has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Heren Health Co (300550)?
Heren Health Co reported trailing-twelve-month revenue of about 433M CNY (latest available figure, as of Jul 9, 2026).
What is the net profit margin of 300550?
The net profit margin of Heren Health Co is about 9.8%, meaning it keeps roughly 9.8% of revenue as net income. Based on the latest reported figures.
Does Heren Health Co pay a dividend?
Heren Health Co currently shows a dividend yield of about 0.21% relative to its recent price (as of Jul 9, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Heren Health Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.